Literature DB >> 24896806

Does pregnancy affect the pharmacokinetics of efavirenz?

Andrew Hill1, Nathan Ford, Marta Boffito, Anton Pozniak, Tim R Cressey.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24896806     DOI: 10.1097/QAD.0000000000000279

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  4 in total

Review 1.  Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.

Authors:  Amy L Slogrove; Polly Clayden; Elaine J Abrams
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

2.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Authors:  Zeruesenay Desta; Roseann S Gammal; Li Gong; Michelle Whirl-Carrillo; Aditya H Gaur; Chonlaphat Sukasem; Jennifer Hockings; Alan Myers; Marelize Swart; Rachel F Tyndale; Collen Masimirembwa; Otito F Iwuchukwu; Sanika Chirwa; Jeffrey Lennox; Andrea Gaedigk; Teri E Klein; David W Haas
Journal:  Clin Pharmacol Ther       Date:  2019-07-05       Impact factor: 6.875

3.  Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.

Authors:  L Dickinson; J Amin; L Else; M Boffito; D Egan; A Owen; S Khoo; D Back; C Orrell; A Clarke; M Losso; P Phanuphak; D Carey; D A Cooper; S Emery; R Puls
Journal:  Clin Pharmacol Ther       Date:  2015-07-14       Impact factor: 6.875

4.  Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?

Authors:  Marco Vitoria; Andrew M Hill; Nathan P Ford; Meg Doherty; Saye H Khoo; Anton L Pozniak
Journal:  J Int AIDS Soc       Date:  2016-02-02       Impact factor: 5.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.